Stock listing

Frankfurt:NV3P NanoViricides, Inc. Aktie

German listing (Frankfurt) of NanoViricides, Inc. · home listing NYSE American:NNVC

Follow NanoViricides, Inc. into a list and get an email when it puts out news.

Share price · FWB:NV3P

€1.18 EUR -0.11 (-8.5%)

Close on Oct 30, 2026

Day range
€1.18 – €1.18 EUROct 30, 2026
Market cap
€30.12M EURAt the close on Oct 30, 2026 · price × 25.52M shares outstanding
NanoViricides, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:NNVC · Home$1.33 USD-0.10 (-7.0%)212,371$1.41$1.45$1.33$1.43Close on Oct 30, 2026
Frankfurt:NV3P€1.18 EUR-0.11 (-8.5%)—€1.18€1.18€1.18€1.29Close on Oct 30, 2026
Ticker
Frankfurt:NV3P
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

Oct 27, 2026

NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials

Oct 20, 2026

Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

Oct 13, 2026

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides

Sep 15, 2026

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

Sep 8, 2026

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Aug 18, 2026

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Aug 10, 2026

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Jul 22, 2026

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Jul 13, 2026

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

Jul 6, 2026

All NanoViricides, Inc. news

Decks

NanoViricides, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
33 in the last 12 months · 57 in all · newest Oct 27, 2026 · oldest 2025
Decks
9 decks · latest Oct 7, 2026

Where NanoViricides, Inc. is listed

ListingExchangeCountryCurrency
NYSE American:NNVC · Home listingNYSE AmericanUnited StatesUSD
LS Exchange:A2PSNFLS ExchangeGermanyEUR
BOATS:NNVCBOATSUnited StatesUSD
Lang & Schwarz:A2PSNFLang & SchwarzGermanyEUR
gettex:NV3PgettexGermanyEUR
Dusseldorf:NV3PDusseldorfGermanyEUR
Frankfurt:NV3P · This pageFrankfurtGermanyEUR
Munich:NV3PMunichGermanyEUR
Stuttgart:NV3PStuttgartGermanyEUR
Tradegate:NV3PTradegateGermanyEUR

Log in to ask 6ix AI your own questions about NanoViricides, Inc.